Parameter
| Biomarker | MR-proADM / ADM | Full name | Mid-regional pro-adrenomedullin / Adrenomedullin | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | ADM: ~5 kDa; MR-proADM: ~5 kDa | Core Functional Dimensions | Diagnosis, prognosis, and evaluation of congestion | |
| Disease | Heart failure | Disease Subtypes | / | ||
| Organ | Vascular endothelial cells, myocardium, adrenal medulla | Test Sample / Technology Platform | Plasma (ELISA, Luminex) | ||
| Pathobiological Mechanisms | Vascular endothelial cells release, regulate the vascular barrier function, and blood vessel tension, volume overload, reflect the vascular congestion state | ||||
| Clinical Availability Status | Clinical validation/guidelines mentioned: - testified MR BACH-proADM predict acute HF AUC = 0.74 90-day mortality (superior to BNP); -ESC guidelines (2021) mention for HF risk stratification | ||||
| Notes and Dynamics | MR-proADM half-life (6 h) longer than ADM (20 min), plasma better stability and suitable for clinical testing; MR in acute HF-proADM > 1.2 nmol/L prompt 30-day mortality HR = 3.85, especially suitable for low BMI (< 25 kg/m²) patients; An anti-ADM antibody (Adrecizumab) has entered phase iia trials for the treatment of severe interstitial hyperemia | ||||